CNBX Pharmaceuticals Inc. (CNBX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CNBX Pharmaceuticals Inc. (CNBX) trades at $0.00 with AI Score 37/100 (Grade D). CNBX Pharmaceuticals Inc. Market cap: $18,502, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for CNBX: CNBX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CNBX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CNBX: 1/1 perspectives are bearish.
How is this calculated? →CNBX Pharmaceuticals Inc. (CNBX) Healthcare & Pipeline Overview
CNBX Pharmaceuticals Inc. is a biopharmaceutical firm specializing in the discovery and development of cannabinoid-based therapies for a range of cancers, including colorectal, breast, and prostate. The company's pipeline features multiple drug candidates, positioning it within the evolving landscape of cannabinoid medicine and oncology research.
What Is the Investment Thesis for CNBX?
CNBX Pharmaceuticals Inc. presents a research-stage investment profile centered on the potential of cannabinoid-based therapies for oncology. The company's extensive pipeline, featuring drug candidates like RCC-33 for colorectal cancer, BRST-33 for breast cancer, and Cannabics SR for cancer anorexia-cachexia syndrome, targets significant unmet medical needs within the multi-billion dollar cancer therapeutics market. The increasing scientific interest and evolving regulatory landscape surrounding cannabinoids could provide a tailwind for CNBX's development efforts. Key value drivers include successful progression through clinical trials, which would validate the efficacy and safety of its formulations, and potential regulatory approvals. However, the company operates with a market capitalization of 19K and currently generates no significant revenue, indicating substantial financial and operational risks inherent in early-stage biopharmaceutical development. Its listing on the OTC Other tier further amplifies concerns regarding liquidity and transparency. Future growth is contingent on securing substantial funding to advance its drug candidates, demonstrating positive clinical outcomes, and navigating complex regulatory pathways. Investors would need to monitor clinical trial milestones, capital raises, and any strategic partnerships closely.
Based on FMP financials and quantitative analysis
CNBX Key Highlights
- Operates with a market capitalization of 19K, reflecting its early-stage development and pre-revenue status.
- Beta of 0.67 suggests lower volatility compared to the broader market, though this can be influenced by low trading volume on OTC markets.
- The company does not pay a dividend, consistent with its focus on reinvesting capital into research and development.
- Focused exclusively on the discovery and development of cannabinoid-based treatments for various cancers, including colorectal, breast, melanoma, and prostate.
- Trades on the OTC Other tier, indicating a less stringent regulatory environment and potential challenges related to liquidity and disclosure.
Who Are CNBX's Competitors?
CNBX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNBX's Key Strengths?
- Specialized focus on cannabinoid-based therapies for oncology, a potentially high-growth niche.
- Diverse pipeline with multiple drug candidates targeting various cancers (colorectal, breast, melanoma, prostate) and supportive care (CACS).
- Flagship product candidate RCC-33 for colorectal cancer addresses a significant market.
- Development of a diagnostic tool (Cannabics CDx) could offer a strategic advantage in personalized medicine.
What Are CNBX's Weaknesses?
- No current revenue generation, relying entirely on R&D funding.
- Very low market capitalization ($0.00B) and listing on OTC Other tier, indicating limited financial resources and market access.
- High operational risk associated with a single employee, potentially limiting capacity and expertise.
- Long and costly drug development cycles with high rates of clinical trial failure.
What Could Drive CNBX Stock Higher?
- Positive preclinical or early-stage clinical trial results for RCC-33 or other pipeline candidates, demonstrating efficacy and safety.
- Successful securing of significant funding rounds or strategic partnerships to advance its drug development pipeline.
- Achievement of key regulatory milestones, such as IND (Investigational New Drug) application acceptance for any of its candidates.
- Continued research and development efforts to expand the understanding and application of cannabinoid-based therapies in oncology.
- Any improvements in disclosure status or potential uplisting to a higher OTC tier, signaling increased transparency and investor confidence.
What Are the Key Risks for CNBX?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- High risk of clinical trial failures, as most drug candidates do not reach market approval, leading to significant R&D investment losses.
- Significant funding challenges due to its early stage, lack of revenue, and low market capitalization, potentially hindering pipeline progression.
- Intense competition from well-funded pharmaceutical companies developing traditional and novel cancer treatments.
- Regulatory hurdles and lengthy approval processes inherent in biopharmaceutical development, delaying potential market entry.
- Limited liquidity and transparency associated with its OTC Other listing, posing challenges for investors and corporate governance.
What Are the Growth Opportunities for CNBX?
- **Advancement of RCC-33 for Colorectal Cancer:** The colorectal cancer treatment market represents a significant opportunity, with global market size projected to reach tens of billions of dollars. RCC-33, an oral cannabinoid capsule, could offer a novel therapeutic approach. Successful progression through Phase 1 and subsequent clinical trials, demonstrating efficacy and safety, would be a major growth catalyst. The timeline for such development typically spans several years, with regulatory approval being the ultimate goal, potentially allowing market entry in the late 2020s or early 2030s.
- **Pipeline Diversification into Multiple Cancer Types:** CNBX's pipeline includes BRST-33 for breast cancer, MLN-33 for melanoma, and PRST-33 for prostate cancer. Each of these represents a multi-billion dollar market segment. Advancing these candidates through preclinical and clinical development could significantly broaden the company's addressable market and reduce reliance on a single drug candidate. The staggered development of these programs provides multiple potential future milestones and market opportunities over the next decade.
- **Development of PLP-33 for Colorectal Polyps:** Targeting lateral spreading or sessile colorectal polyps during colonoscopy with PLP-33 offers a unique preventative or early-stage intervention opportunity. The market for colorectal polyp management, while distinct from advanced cancer treatment, is substantial given the prevalence of polyps and the importance of early detection and removal to prevent cancer. Successful development could position CNBX in a niche with potentially fewer direct competitors and a faster path to market compared to late-stage cancer therapies, possibly within the next five to seven years.
- **Commercialization of Cannabics SR for Cancer Anorexia-Cachexia Syndrome:** Cancer anorexia-cachexia syndrome (CACS) affects a significant portion of cancer patients, severely impacting quality of life and treatment outcomes. The global market for CACS treatments is projected to grow, driven by the need for supportive care. Cannabics SR, a lipid-based cannabinoid capsule, could provide a much-needed therapeutic option. Demonstrating clinical effectiveness and securing regulatory approval for this supportive care indication could offer a relatively quicker path to market and revenue generation compared to primary cancer treatments, potentially within the next five years.
- **Leveraging Cannabics CDx as a Diagnostic Tool:** Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool, represents an opportunity in the precision medicine market. This tool could enhance the value proposition of CNBX's therapeutic pipeline by enabling personalized treatment strategies, potentially improving patient outcomes and accelerating drug development. The companion diagnostics market is growing rapidly, driven by the demand for tailored therapies. Successful validation and commercialization of Cannabics CDx could create a distinct revenue stream and strategic advantage, potentially within the next three to five years, by partnering with other pharmaceutical companies or diagnostic labs.
What Opportunities Does CNBX Have?
- Growing acceptance and research into the therapeutic potential of cannabinoids in medicine.
- Potential for strategic partnerships or licensing agreements with larger pharmaceutical companies.
- Expansion into new therapeutic areas or indications beyond current pipeline targets.
- Advancements in precision medicine could enhance the value of its diagnostic tool, Cannabics CDx.
What Threats Does CNBX Face?
- Significant regulatory hurdles and lengthy approval processes for new drug candidates.
- Intense competition from established pharmaceutical companies and other biotech firms in oncology.
- Risk of clinical trial failures, which would severely impact the company's viability.
- Challenges in securing adequate funding for ongoing research and development activities.
- Intellectual property challenges and patent expirations in the future.
What Are CNBX's Competitive Advantages?
- Specialized focus on cannabinoid-based therapies for oncology, a niche with growing scientific interest.
- Proprietary formulations and intellectual property (if patents are secured) for specific cannabinoid drug candidates like RCC-33 and Cannabics SR.
- Early-mover advantage in certain cannabinoid applications within oncology, potentially establishing expertise and clinical data ahead of broader competition.
- Diversified pipeline targeting multiple cancer types and supportive care, spreading potential success across various indications.
What Does CNBX Do?
CNBX Pharmaceuticals Inc., established in 2004 and headquartered in Bethesda, Maryland, is a biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-based treatments and therapies for various oncological conditions. The company, which operates as a subsidiary of Cannabics Inc., underwent a name change from Cannabics Pharmaceuticals Inc. in March 2022 to reflect its refined strategic focus. At the core of its development efforts is RCC-33, an oral capsule formulation of cannabinoids specifically engineered to address colorectal cancer, representing a significant potential advancement in targeted cancer therapeutics. Beyond its flagship candidate, CNBX maintains a robust and diversified development pipeline. This includes PLP-33, a formulation designed to target lateral spreading or sessile colorectal polyps during colonoscopy, offering a potential non-invasive treatment option. The company is also actively pursuing BRST-33 for breast cancer, MLN-33 for melanoma, and PRST-33 for prostate cancer, indicating a broad commitment to addressing multiple prevalent cancer types with cannabinoid-based solutions. In addition to these specific cancer treatments, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids aimed at managing cancer anorexia-cachexia syndrome, a debilitating condition often associated with advanced cancer. Furthermore, the company is innovating with Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool, which could potentially personalize cancer treatment by identifying patient-specific responses to therapies. With a lean operational structure, the company's strategic focus remains on advancing its pipeline through clinical development stages, leveraging the therapeutic potential of cannabinoids in oncology.
What Products and Services Does CNBX Offer?
- Discovers and develops cannabinoid-based treatments for various cancers.
- Focuses on its flagship product candidate, RCC-33, for colorectal cancer.
- Develops PLP-33 for lateral spreading or sessile colorectal polyps during colonoscopy.
- Has a pipeline including BRST-33 for breast cancer, MLN-33 for melanoma, and PRST-33 for prostate cancer.
- Develops Cannabics SR, a lipid-based capsule for managing cancer anorexia-cachexia syndrome.
- Innovates with Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool.
- Operates as a biopharmaceutical firm, conducting research and clinical development.
- Aims to commercialize cannabinoid-based therapies for oncological conditions.
How Does CNBX Make Money?
- Primarily engaged in research and development (R&D) of novel drug candidates.
- Future revenue generation is anticipated through the commercialization of approved cannabinoid-based pharmaceuticals.
- Potential for licensing agreements or partnerships with larger pharmaceutical companies for drug development and distribution.
- May generate revenue from diagnostic tools like Cannabics CDx, either through sales or service provision.
What Industry Does CNBX Operate In?
CNBX Pharmaceuticals Inc. operates within the highly specialized and competitive biotechnology industry, specifically targeting the oncology sector with cannabinoid-based therapies. The global market for cancer therapeutics is substantial and continues to grow, driven by an aging population, increasing cancer incidence, and advancements in treatment modalities. Within this landscape, the niche of cannabinoid-based pharmaceuticals is emerging, fueled by growing research into the anti-tumor and palliative properties of cannabinoids. While still a nascent field compared to traditional oncology treatments, there is increasing interest from both scientific and patient communities. CNBX's strategy to develop multiple drug candidates across various cancer types positions it to potentially capture market share in this evolving segment. However, the industry is characterized by high R&D costs, lengthy clinical trial processes, stringent regulatory hurdles, and intense competition from established pharmaceutical giants and other biotech firms developing novel cancer treatments. CNBX's success will depend on its ability to differentiate its cannabinoid formulations and demonstrate superior efficacy and safety profiles.
Who Are CNBX's Key Customers?
- Future patients suffering from various cancers, including colorectal, breast, melanoma, and prostate cancer.
- Patients experiencing cancer anorexia-cachexia syndrome requiring supportive care.
- Oncologists and other healthcare providers prescribing cannabinoid-based therapies.
- Potential pharmaceutical partners for co-development, licensing, or distribution agreements.
- Diagnostic laboratories or research institutions utilizing the Cannabics CDx tool.
F-Score 2/9Financial Health
CNBX Pharmaceuticals Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CNBX Valuation & Market Position
With a 19K market cap, CNBX Pharmaceuticals Inc. sits in the micro-cap segment of the market. Relative to its peer group, CNBX's quantitative score of 37/100 is below the peer average of 76/100.
ROE 18%Key Financial Metrics
Return on equity for CNBX Pharmaceuticals Inc. stands at 18.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
CNBX Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bethesda, US. The company is led by CEO Eyal Barad. CNBX has traded publicly since 2007.
CNBX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- CNBX's recent insider buying suggests those in the know see long-term value, signaling confidence despite market volatility.
- The community's growing interest in cannabis-based pharmaceuticals could drive positive attention and investment towards CNBX.
- Positive clinical trial updates (if any) could significantly shift market perception, attracting both retail and institutional investors.
- Increased media coverage highlighting the potential of CNBX's specific drug candidates could boost investor sentiment.
Bear Case
- Recent negative sentiment within the social trading community might indicate concerns about CNBX's short-term prospects.
- Lack of significant news or developments in the past month could be interpreted as stagnation, deterring potential investors.
- Competitor activity in the cannabinoid pharmaceutical space could overshadow CNBX, impacting its market share and visibility.
- General market uncertainty and risk aversion could lead investors to shy away from smaller, less established pharmaceutical companies like CNBX.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
CNBX Latest News
No recent news available for CNBX.
CNBX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNBX.
Price Targets
Wall Street price target analysis for CNBX.
CNBX MoonshotScore
What does this score mean?
The MoonshotScore rates CNBX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Eyal Barad
CEO
The provided source data indicates Eyal Barad as the CEO of CNBX Pharmaceuticals Inc., managing the company's operations. Specific details regarding Mr. Barad's educational background, prior career history, and previous leadership roles are not available in the provided information. His experience would likely encompass aspects of biopharmaceutical development, corporate strategy, and potentially fundraising, given the nature of the company's business model and stage of development.
Track Record: Information detailing Eyal Barad's specific achievements, strategic decisions, or key company milestones under his leadership is not provided in the source data. As CEO of CNBX Pharmaceuticals Inc., his responsibilities would inherently include guiding the company's research and development initiatives, managing its pipeline of cannabinoid-based therapies, and overseeing its operational and financial strategy, especially given the company's lean operational structure with one employee.
CNBX OTC Market Information
CNBX Pharmaceuticals Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group's three marketplaces. Unlike companies listed on major exchanges like the NYSE or NASDAQ, which must meet stringent financial, governance, and disclosure requirements, companies on the OTC Other tier have minimal to no public disclosure obligations. This tier is typically for companies that are unwilling or unable to provide information to the public, often due to financial distress, shell status, or simply being very early-stage. This contrasts sharply with the OTCQX and OTCQB tiers, which have higher financial and disclosure standards, aiming for more transparent and established companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no public disclosure, making it difficult to assess financial health and operational progress.
- Extremely low liquidity and wide bid-ask spreads, leading to challenges in trading and price discovery.
- High susceptibility to market manipulation due to low trading volume and lack of regulatory oversight.
- Lack of analyst coverage and institutional interest, resulting in limited public information and scrutiny.
- Potential for significant price volatility and difficulty in accurately valuing the company's shares.
- Verify the company's current financial statements and disclosures, if any are available, directly from the company or regulatory filings.
- Research the background and track record of management and key personnel, beyond what is publicly available.
- Assess the viability and stage of development of its product pipeline, including any preclinical or clinical trial data.
- Investigate any existing or potential funding sources and the company's burn rate.
- Understand the competitive landscape and regulatory environment specific to cannabinoid-based oncology treatments.
- Evaluate the company's intellectual property portfolio and patent protection for its drug candidates.
- Examine any legal or regulatory actions against the company or its management.
- Incorporated in 2004, indicating a long-standing corporate entity, albeit with a name change in 2022.
- Operates as a subsidiary of Cannabics Inc., suggesting a broader corporate structure and backing.
- Has a clearly defined and diversified pipeline of specific drug candidates targeting various cancers and supportive care.
- Headquartered in Bethesda, Maryland, providing a physical presence in a recognized biotech hub.
What Investors Ask About CNBX Pharmaceuticals Inc. (CNBX) — Healthcare
What does CNBX Pharmaceuticals Inc. do?
CNBX Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of cannabinoid-based treatments for various cancers. Its core business revolves around advancing a pipeline of drug candidates, including RCC-33 for colorectal cancer, PLP-33 for colorectal polyps, BRST-33 for breast cancer, MLN-33 for melanoma, and PRST-33 for prostate cancer. Additionally, the company is developing Cannabics SR for cancer anorexia-cachexia syndrome and Cannabics CDx, an ex-vivo diagnostic tool. Essentially, CNBX aims to leverage the therapeutic potential of cannabinoids to address significant unmet medical needs in oncology, from primary cancer treatment to supportive care and personalized diagnostics.
What are the main risks for CNBX Pharmaceuticals Inc.?
Investing in CNBX Pharmaceuticals Inc. carries substantial risks, primarily due to its early-stage drug development nature and financial profile. A major risk is the high probability of clinical trial failures, which can render years of research and significant capital investment unproductive. The company currently generates no revenue and has a market capitalization of 19K, implying ongoing challenges in securing sufficient funding to advance its extensive pipeline. Its listing on the OTC Other tier means limited public disclosure, low liquidity, and potential for significant price volatility, complicating investment and exit strategies. Intense competition from larger, well-funded pharmaceutical companies, coupled with stringent and lengthy regulatory approval processes, further exacerbates the risk profile for CNBX.
How does CNBX Pharmaceuticals Inc. plan to fund its drug development?
As an early-stage biopharmaceutical company with no current revenue, CNBX Pharmaceuticals Inc. relies on external funding to finance its extensive drug development pipeline. The primary mechanisms for funding typically involve raising capital through equity offerings, such as private placements or public stock sales, which can dilute existing shareholders. Additionally, the company may seek non-dilutive funding through grants, strategic partnerships, or licensing agreements with larger pharmaceutical companies that could provide upfront payments or milestone-based funding in exchange for development rights or commercialization. Given its OTC Other listing and low market capitalization, securing substantial capital will be a critical and ongoing challenge for CNBX to progress its cannabinoid-based therapies through preclinical and clinical trials.
What are the key factors to evaluate for CNBX?
CNBX Pharmaceuticals Inc. (CNBX) holds an AI score of 37/100 (low). Not financial advice.
How frequently does CNBX data refresh on this page?
CNBX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CNBX's recent stock price performance?
CNBX Pharmaceuticals Inc. (CNBX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on cannabinoid-based therapies for oncology, a potentially high-growth niche. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CNBX overvalued or undervalued right now?
Valuing CNBX Pharmaceuticals Inc. (CNBX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CNBX?
Before investing in CNBX Pharmaceuticals Inc. (CNBX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data provided, impacting depth of quantitative analysis.
- No specific FMP PEER TICKERS provided in source data.
- CEO background and track record details are not available in the provided source data.